Daily Stock Analysis, ASMB, Assembly Biosciences Inc, priceseries

Assembly Biosciences Inc. Daily Stock Analysis
Stock Information
Open
23.32
Close
23.30
High
23.45
Low
22.61
Previous Close
23.32
Daily Price Gain
-0.02
YTD High
28.18
YTD High Date
Mar 15, 2017
YTD Low
11.85
YTD Low Date
Jan 3, 2017
YTD Price Change
11.11
YTD Gain
91.14%
52 Week High
28.18
52 Week High Date
Mar 15, 2017
52 Week Low
5.00
52 Week Low Date
Jun 27, 2016
52 Week Price Change
18.21
52 Week Gain
357.76%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 3. 2015
8.65
Mar 11. 2015
14.28
25 Trading Days
65.14%
Link
LONG
Apr 7. 2015
15.09
Apr 22. 2015
18.16
11 Trading Days
20.31%
Link
LONG
May 20. 2015
14.31
Jun 10. 2015
16.89
14 Trading Days
18.06%
Link
LONG
Jun 25. 2015
17.01
Jul 7. 2015
18.27
7 Trading Days
7.40%
Link
LONG
Sep 16. 2015
13.78
Sep 21. 2015
14.61
3 Trading Days
6.02%
Link
LONG
Oct 28. 2015
10.14
Oct 29. 2015
10.69
1 Trading Days
5.37%
Link
LONG
Aug 16. 2016
5.90
Aug 31. 2016
6.22
11 Trading Days
5.39%
Link
LONG
Oct 4. 2016
7.69
Nov 2. 2016
13.05
21 Trading Days
69.67%
Link
LONG
Jan 12. 2017
13.79
Feb 10. 2017
19.80
20 Trading Days
43.58%
Link
Company Information
Stock Symbol
ASMB
Exchange
NasdaqCM
Company URL
www.assemblybio.com
Company Phone
(212) 554-4388
CEO
Derek A. Small
Headquarters
Indiana
Business Address
11711 N. MERIDIAN STREET, SUITE 310, CARMEL, IN 46032
Sector
Equity
Industry Category
Drugs
Industry Group
Drug Manufacturers - Major
CIK
0001426800
About

Assembly Biosciences, Inc. is a biotechnology company, which engages in the development of two innovative platform programs: hepatitis b virus and microbiome program. It focuses on advancing science and enhancing the health and well-being of patients with hard-to-treat infectious diseases. The company was founded on October 7, 2005 and is headquartered in New York, NY.

Description

Assembly Biosciences, Inc., a biotechnology company, develops oral therapeutics for the treatment of hepatitis B virus (HBV) infection and to restore health to a dysbiotic microbiome in the United States. It is involved in developing core protein allosteric modulators that modulate the HBV core protein, a polyfunctional viral protein at various points in the viral lifecycle. The company also develops microbiome program, a platform that includes the identification and selection process to strain isolation and growth under cGMP conditions, and a patent pending delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. Its lead drug candidate from the platform is AB-M101, is in development for the treatment of C. difficile- infections. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was founded in 2005 and is based in Carmel, Indiana.